StockNow
Log in
U.S. Markets

Elevance (ELV) notes that it remains confident in returning to "at least" 12% adjusted EPS growth in 2027, citing progress across the portfolio

StockNow breaking-news AI analysis

Elevance Health maintains its 12% EPS growth target for 2027, leveraging AI-driven efficiency, Medicare Advantage margin recovery, and strong Commercial segment demand to overcome 2026 transitional challenges.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYU.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement